^
Association details:
Evidence:
Evidence Level:
Sensitive: D – Preclinical
New
Title:

An alpha-fetoprotein-maytansine conjugate for the treatment of AFP receptor expressing tumors

Excerpt:
An alpha-fetoprotein-maytansine conjugate for the treatment of AFP receptor expressing tumors....For ACT-903, tumors continued shrinking even after treatment completion, becoming undetectable in 9 of 10 animals….The efficacy and tolerability of ACT-903 in an animal tumor model supports advancing this conjugate toward clinical use with a regimen of either once a week or once every other week administration.
DOI:
https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.16_suppl.e15056